RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 -- It is with deep sadness that Pappas Capital announces the passing of Dr. Ernest Mario, Senior Venture Partner and one of the founders...
Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough is Published in The Lancet
News | 11. 25. 2014
Afferent Pharmaceuticals
SAN MATEO, Calif.--(BUSINESS WIRE)-- Afferent Pharmaceuticals today announced publication of results from a Phase 2 clinical trial demonstrating that the company’s novel drug candidate, AF-219, reduced daytime cough frequency by 75% compared to placebo in patients with treatment-refractory chronic cough. These data are featured in an article titled, "P2X3 Receptor Antagonist (AF-219) in Refractory Chronic Cough: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Study," which is appearing online in The Lancet. These results support Afferent’s current development strategy to initiate a Phase 2b clinical trial early in 2015. AF-219 is a selective, non-narcotic and orally administered agent that targets the mechanism by which certain nerve fibers become hyper-sensitized and lead to chronic and debilitating symptoms such as cough.
